Eris Lifesciences Limited share price

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, GLP-1, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram monitoring, continuous glucose monitoring system, sleep device, antenatal care, and early neuropathy screening solutions, as well a…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty Microcap 250NSE: ERISISIN INE406M01024

16 Oct 2026, 3:29 PM IST₹1,144.40▼ 4.40 (0.38%)

Market Cap₹ 15,877 Cr.
Current Price₹ 1,144.40
High / Low₹ 1,740 / 1,131
Stock P/E24.4
Book Value₹ 285
Dividend Yield1.26 %
ROCE15.7 %
ROE18.30 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 46.96
Price / Book4.01
OPM27.0 %
Debt / Equity0.60
Sales growth (5Y)20.9 %
Profit growth (5Y)12.8 %
Promoter holding69.8 %
EV / EBITDA16.0
Beta-0.03
All-time high₹ 1,910

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
ERIS	-12.19%	-23.11%	-21.91%	-23.99%	-27.89%	+9.63%	+6.48%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Eris Lifesciences Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹15,877 crore.
It trades at 24.4 times its last 12 months' earnings and 4.0 times book value.
Revenue grew 20.9% a year over the last 5 years, profit 12.8% a year.
Return on equity was 18.3% and return on capital employed 15.7% in the latest year.
Debt was 0.60 times shareholders' equity.
The share price is 34.2% below its 52-week high and down 27.9% over one year.
Promoters and insiders hold about 69.8%; institutions about 22.3%.

Pros

Sales have grown 20.9% a year over the last 5 years.
Latest quarter (Jun 2026): sales up 13% and profit up 15% from a year ago.
Healthy return on equity of 15.9% on average over the last 3 years.
Trades at 24.4 times earnings, below its 3-year median of 44.0.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Eris Lifesciences Limited

Employees: 2,758
Head office: Ahmedabad
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty Microcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Eris Lifesciences	1,144.40	24.4	15,877	1.26	143	14.56	873	12.97	15.7	18.3	4.01	27.0	0.60	69.84	3,129	20.9
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 39 Co.	1,712.85	30.8	25,243	0.35	679	14.43	5,999	18.81	15.3	16.8	4.84	17.0	0.30	55.20	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	467	505	486	551	720	739	727	705	773	792	807	757	873
YOY Sales Growth %		9.73%	14.89%	36.77%	54.24%	46.24%	49.59%	28.02%	7.40%	7.23%	11.00%	7.27%	12.97%
	297	324	311	402	470	477	477	453	496	504	526	483	577
Material Cost %	17%	19%	18%	21%	25%	25%	24%	24%	24%	26%	28%	24%	27%
Employee Cost %	22%	19%	20%	19%	18%	17%	17%	17%	19%	17%	17%	18%	18%
Other Expenses %	25%	26%	25%	33%	22%	22%	24%	23%	22%	21%	20%	21%	21%
Operating Profit	170	181	176	148	250	262	250	252	277	288	282	274	296
OPM %	36%	36%	36%	27%	35%	35%	34%	36%	36%	36%	35%	36%	34%
	1	3	4	15	2	7	4	8	3	3	0	2	2
Exceptional items											-17
Interest	17	16	18	33	60	59	57	54	49	50	49	46	47
Depreciation	41	42	46	54	76	80	81	77	71	69	70	70	72
Profit before tax	112	126	116	77	115	129	116	129	160	172	145	161	180
	17%	3%	12%	-4%	22%	25%	25%	21%	22%	22%	25%	-75%	20%
Current tax	22	25	19	16	25	30	25	31	56	71	17	12	31
Deferred tax	-3	-21	-5	-19	1	3	4	-5	-20	-33	19	-132	5
	94	122	101	80	89	96	87	102	125	134	109	279	143
Profit from associates								0	1	0	0	-1	-0
Minority share	-1	-1	-1	9	6	5	3	9	7	14	9	-3	1
Profit to shareholders	95	123	103	71	83	92	84	94	118	120	100	282	142
YOY Profit Growth %		2.46%	1.23%	29.53%	-4.52%	-21.22%	-14.32%	28.53%	39.90%	39.56%	25.19%	172.69%	14.56%
EPS in Rs	6.97	9.08	7.55	5.22	6.11	6.73	6.15	6.90	8.66	8.82	7.32	20.60	10.28
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	411	410	324	341	457	429	400	405	579	651	315	277	444
YOY Sales Growth %	25.10%	15.29%	-2.29%	8.49%	11.04%	4.65%	23.22%	18.60%	26.70%	51.72%	-21.12%	-31.49%	-23.27%
	256	265	250	262	333	294	300	284	362	354	238	256	324
Material Cost %	18%	19%	20%	19%	29%	29%	30%	31%	31%	30%	35%	50%	36%
Employee Cost %	22%	20%	25%	23%	23%	21%	22%	20%	16%	13%	26%	28%	20%
Other Expenses %	22%	26%	32%	34%	22%	18%	24%	19%	15%	11%	14%	14%	16%
Operating Profit	156	144	74	79	123	135	100	121	216	297	77	22	120
OPM %	38%	35%	23%	23%	27%	31%	25%	30%	37%	46%	25%	8%	27%
	4	7	3	20	5	14	8	17	23	24	25	27	26
Exceptional items											-15
Interest	7	7	15	29	56	56	55	53	45	47	45	43	42
Depreciation	20	25	28	29	46	46	47	43	38	39	39	39	40
Profit before tax	133	120	35	42	27	46	6	41	156	235	4	-33	64
	16%	2%	9%	5%	36%	39%	70%	26%	36%	36%	21%		25%
Current tax	22	22	6	8	5	9		9	27	41	1	-8	10
Deferred tax	0	-20	-3	-6	5	9	4	2	29	44	0	-17	6
	111	118	32	40	17	28	2	30	100	150	3	-9	48
YOY Profit Growth %	15.85%	2.27%	-68.15%	-55.02%	-84.61%	-76.15%	-94.38%	-22.88%	486.80%	432.28%	73.60%	-128.22%	-51.70%
EPS in Rs	8.14	8.66	2.33	2.90	1.25	2.06	0.13	2.24	7.34	10.98	0.23	-0.63	3.49
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	856	982	1,074	1,212	1,347	1,685	2,009	2,894	3,129	3,230
YOY Sales Growth %		14.79%	9.36%	12.83%	11.15%	25.10%	19.23%	44.02%	8.15%
	534	637	706	781	862	1,148	1,334	1,876	2,009	2,090
Material Cost %	16%	16%	16%	20%	19%	21%	19%	25%	25%	26%
Employee Cost %	18%	19%	19%	19%	19%	21%	20%	17%	18%	18%
Other Expenses %	28%	30%	31%	26%	26%	27%	27%	23%	21%	21%
Operating Profit	322	345	368	431	485	537	675	1,017	1,120	1,140
OPM %	38%	35%	34%	36%	36%	32%	34%	35%	36%	35%
	26	32	15	9	26	11	24	18	8	7
Exceptional items									-17	-17
Interest	11	23	2	2	4	26	85	231	193	191
Depreciation	26	36	50	43	65	117	183	315	280	281
Profit before tax	312	317	331	394	442	405	431	489	638	658
	6%	8%	11%	10%	8%	8%	8%	23%	-1%	-1%
Current tax	69	71	61	69	82	75	82	112	157
Deferred tax	-52	-45	-26	-30	-45	-44	-48	2	-166
	295	291	297	355	406	374	397	375	648	666
Profit from associates								0	0	-1
Minority share	1	0			-0	-8	5	23	28	22
Profit to shareholders	294	291		355	406	382	392	352	620	644
YOY Profit Growth %		-1.30%	1.84%	19.77%	14.26%	-7.79%	6.12%	-5.64%	72.82%
EPS in Rs	21.39	21.15	21.61	26.16	29.89	28.10	28.82	25.85	45.33	47.02
Dividend Payout %					20%	26%		28%

Compounded Sales Growth

5 Years:: 21%
3 Years:: 23%
TTM:: 10%

Compounded Profit Growth

5 Years:: 13%
3 Years:: 20%
TTM:: 62%

Stock Price CAGR

5 Years:: 6%
3 Years:: 10%
1 Year:: -28%

Return on Equity

4 Years:: 16%
Last Year:: 18%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	761	897	1,020	1,109	1,216	1,331	1,487	1,698	1,822	1,687
YOY Sales Growth %		17.87%	13.80%	8.68%	9.64%	9.46%	11.72%	14.20%	7.30%
	445	563	665	692	732	826	1,033	1,211	1,209	1,171
Material Cost %	14%	15%	16%	18%	16%	18%	19%	29%	34%	36%
Employee Cost %	17%	19%	19%	19%	18%	19%	22%	21%	19%	20%
Other Expenses %	27%	29%	30%	26%	25%	25%	28%	21%	13%	13%
Operating Profit	316	334	356	417	484	505	454	487	612	516
OPM %	42%	37%	35%	38%	40%	38%	31%	29%	34%	31%
	28	32	15	10	29	17	35	36	98	102
Exceptional items									-15	-15
Interest	10	23	2	1	3	21	57	220	180	177
Depreciation	22	32	45	38	51	65	102	182	154	157
Profit before tax	312	312	324	389	459	437	329	120	362	270
	6%	8%	10%	10%	9%	9%	9%	36%	33%	29%
Current tax	68	69	57	70	80	76	58	22	61
Deferred tax	-50	-42	-25	-32	-39	-38	-29	21	57
	294	285	291	351	417	398	300	77	244	192
YOY Profit Growth %		-2.82%	2.06%	20.37%	18.99%	-4.60%	-24.70%	-74.18%	215.35%
EPS in Rs	21.36	20.75	21.23	25.82	30.70	29.27	22.04	5.69	17.86	14.07
Dividend Payout %					20%	25%		129%

Compounded Sales Growth

5 Years:: 10%
3 Years:: 11%
TTM:: -7%

Compounded Profit Growth

5 Years:: -7%
3 Years:: -15%
TTM:: 20%

Stock Price CAGR

5 Years:: 6%
3 Years:: 10%
1 Year:: -28%

Return on Equity

4 Years:: 16%
Last Year:: 18%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	14	14	14	14
Reserves	2,182	2,573	2,841	3,889
	877	2,781	2,478	2,359
Long term borrowings	644	655	1,738	956
Short term borrowings	186	2,081	684	1,354
	595	1,673	1,704	1,104
Trade payables	125	219	332	330
Minority interest	25	636	417	-7
Current liabilities	443	2,532	1,385	2,077
Total Liabilities	3,667	7,040	7,036	7,366
	389	569	756	981
Gross block	483	714	977	1,199
Accumulated depreciation	93	145	221	218
Goodwill & intangibles	2,212	3,781	4,645	4,479
CWIP	33	30	94	273
	3,245	6,442	6,187	6,111
Inventories	131	189	335	437
Trade receivables	293	422	459	680
Cash & equivalents	56	94	200	55
Current assets	765	2,302	1,226	1,540
Total Assets	3,667	7,040	7,036	7,366

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	292	486	1,065	538
Profit for the year	382	392	352	620
Working capital changes	-176	-99	126	-458
Direct taxes paid	-77	-101	-98	-124
	-982	-1,855	-80	-369
Fixed assets purchased	-841	-129	-155	-297
Fixed assets sold	0		0	0
Investments purchased	-30	-1,212		-35
Investments sold	520	48	1,287	17
	688	1,380	-881	-314
Proceeds from borrowings	1,168	1,623	1,400	117
Repayment of borrowings	-350	-159	-799	-282
Interest paid	-23	-77	-145	-193
Dividends paid	-100		-100
Net Cash Flow	-2	11	104	-145
Free Cash Flow	-550	357	910	241

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	17.4%	16.4%	12.9%	18.3%
ROCE	—	13.4%	11.4%	12.7%	15.7%
Operating margin	—	25.4%	24.9%	24.4%	27.0%
Net margin	—	23.0%	19.7%	12.2%	19.9%
Debt / equity	—	0.40	1.08	0.87	0.60
Current ratio	—	1.73	0.91	0.89	0.74
Debtor days	—	64	77	58	80
Inventory days	—	134	178	167	195
Days payable	—	128	206	166	147
Cash conversion cycle	—	70	49	59	128
Working capital days	—	71	-42	-20	-63

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 54.14%
FIIs 5.75%
DIIs 20.72%
Public 19.40%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	54.91%	54.90%	54.90%	54.88%	54.87%	54.86%	54.85%	54.83%	54.85%	54.85%	53.92%	54.14%
	13.20%	13.14%	14.27%	14.59%	8.01%	8.35%	8.43%	8.40%	7.21%	6.85%	6.39%	5.75%
Foreign portfolio investors (Cat. I)	13.10%	13.00%	14.13%	14.44%	7.70%	8.12%	8.11%	7.76%	6.62%	6.33%	6.02%	5.43%
Foreign portfolio investors (Cat. II)	0.10%	0.13%	0.14%	0.15%	0.31%	0.24%	0.32%	0.63%	0.59%	0.52%	0.37%	0.33%
	14.53%	14.56%	15.63%	16.23%	18.64%	18.06%	18.07%	18.17%	19.36%	20.32%	20.35%	20.72%
Mutual funds	13.86%	13.85%	14.92%	14.52%	17.03%	16.52%	16.59%	16.78%	17.33%	18.26%	18.22%	18.88%
Insurance companies				0.90%	0.92%	0.74%	0.69%	0.64%	1.20%	1.25%	1.31%	1.13%
Alternative investment funds	0.66%	0.70%	0.71%	0.81%	0.69%	0.81%	0.79%	0.76%	0.83%	0.80%	0.82%	0.70%
	17.37%	17.41%	15.19%	14.30%	18.47%	18.72%	18.66%	18.59%	18.57%	17.99%	19.33%	19.40%
Retail (up to ₹2 lakh)	2.29%	2.53%	2.68%	2.47%	2.41%	2.65%	2.53%	2.51%	2.57%	2.62%	2.61%	2.65%
HNIs (above ₹2 lakh)	13.18%	13.14%	11.56%	11.06%	8.11%	6.64%	6.63%	6.61%	6.55%	5.88%	7.45%	7.45%
NRIs	0.27%	0.21%	0.22%	0.16%	0.16%	0.18%	0.17%	0.17%	0.17%	0.16%	0.16%	0.16%
Bodies corporate	1.35%	1.35%	0.61%	0.50%	0.42%	0.38%	0.38%	0.34%	0.31%	0.33%	0.27%	0.29%
No. of Shareholders	42,245	46,496	51,753	44,176	46,346	53,314	50,087	52,225	59,438	54,713	51,656	50,798

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Eris Lifesciences

Holder (above 1%)	Stake
HDFC Small Cap FundMutual fund	8.33%
Franklin India Small Cap FundMutual fund	4.29%
Uti-Flexi Cap FundMutual fund	1.58%
HSBC Small Cap FundMutual fund	1.03%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 18.88% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 29 May 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Eris Lifesciences Limited

What is the share price of Eris Lifesciences Limited today?

Eris Lifesciences Limited (ERIS) last traded at ₹1,144.40 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Eris Lifesciences Limited?

About ₹15,877 crore at the latest price.

What is the P/E ratio of Eris Lifesciences Limited?

About 24.4 times its earnings over the last 12 months.

Is Eris Lifesciences Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Eris Lifesciences Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Eris Lifesciences Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Eris Lifesciences Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Eris Lifesciences

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Eris Lifesciences Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next